Cancer-drug discovery and cardiovascular surveillance

N Engl J Med. 2013 Nov 7;369(19):1779-81. doi: 10.1056/NEJMp1313140. Epub 2013 Nov 1.

Authors

John D Groarke¹, Susan Cheng, Javid Moslehi

Affiliation

¹ From the Cardio-Oncology Program at the Dana-Farber Cancer Institute (J.D.G., J.M.) and the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital (J.D.G., S.C., J.M.); and Harvard Medical School (J.D.G., S.C., J.M.) - all in Boston.

PMID: 24180496
DOI: 10.1056/NEJMp1313140

No abstract available

MeSH terms

Antineoplastic Agents / adverse effects
Cardiovascular System / drug effects
Drug Discovery*
Fusion Proteins, bcr-abl / antagonists & inhibitors*
Fusion Proteins, bcr-abl / genetics
Humans
Imidazoles / adverse effects*
Imidazoles / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors*
Protein-Tyrosine Kinases / genetics
Pyridazines / adverse effects*
Pyridazines / therapeutic use
Pyrimidines / adverse effects*
Pyrimidines / therapeutic use
Vascular Diseases / chemically induced*

Substances

Antineoplastic Agents
Imidazoles
Protein Kinase Inhibitors
Pyridazines
Pyrimidines
ponatinib
Protein-Tyrosine Kinases
Fusion Proteins, bcr-abl
nilotinib